Dark

Check out our Dark Pool Levels

VACC
Vaccitech plc
stock NASDAQ

Inactive

Nov 6, 2023

5.00USD+11.359%(+0.51)165,353

Pre-market

0.00USD-100.000%(-4.49)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 18, 2022

03:00AM EST Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600, in patients with the most common type of lung cancer. GlobeNewswire Inc

Jan 13, 2022

04:34PM EST Vaccitech to Host Virtual KOL Event on VTP-300, a Potential GlobeNewswire Inc

Dec 15, 2021

07:19AM EST HC Wainwright & Co. Maintains Buy on Vaccitech, Lowers Price Target to $23 Benzinga

Dec 14, 2021

08:22AM EST The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks Benzinga

Dec 13, 2021

04:06PM EST Vaccitech Acquires Avidea Technologies For $40M Benzinga

04:05PM EST Vaccitech acquires Avidea Technologies to expand product pipeline GlobeNewswire Inc

Dec 7, 2021

09:49AM EST Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial Benzinga

08:27AM EST Vaccitech Reports Interim Efficacy Analysts In Phase 1b/2a Clinical Study In Chronic HBV; Says Data Demonstrated 'Noted Changes' In Surface Antigen Levels Benzinga

08:00AM EST Interim data from 27 patients, who had completed 3 months in the HBV002 study in chronic Hepatitis B (CHB) patients, demonstrated noted changes in surface antigen (HBsAg) levels, especially in the group receiving low-dose nivolumab with the heterologous boost (VTP-300). GlobeNewswire Inc

Nov 29, 2021

03:01AM EST BioConnection to manufacture clinical trial material for Nykode Therapeutics' PR Newswire

Nov 24, 2021

09:20AM EST Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler GlobeNewswire Inc

Nov 23, 2021

01:00AM EST Vaccibody Becomes Nykode Therapeutics - a New Name and Identity to Signify a New Phase of Growth and Development Business Wire

12:45AM EST Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases Business Wire

Nov 15, 2021

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

Nov 12, 2021

08:00AM EST Interim data from two studies, HBV001 and HBV002, showed that in chronic Hepatitis B (CHB) patients the heterologous prime-boost vector combination, ChAdOx1-HBV + MVA-HBV (VTP-300), induced robust T cells against targeted hepatitis B viral antigens. GlobeNewswire Inc

07:28AM EST Vaccitech Q3 EPS $(0.13) Down From $0.01 YoY Benzinga

07:00AM EST Vaccitech Reports Third Quarter 2021 Financial Results and Recent GlobeNewswire Inc

Nov 10, 2021

08:00AM EST Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Bill Enright, Chief Executive Officer, will be presenting at the Jefferies London Healthcare Conference. GlobeNewswire Inc

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Nov 4, 2021

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

04:00AM EDT The Phase 1 clinical trial was conducted by The King Abdullah International Medical Research Centre (KAIMRC), in the Kingdom of Saudi Arabia (KSA), in partnership with the University of Oxford. Vaccitech retains commercial rights to this vaccine. GlobeNewswire Inc

Oct 18, 2021

08:04AM EDT Vaccitech Announces Data Presentations at AASLD's Liver Meeting 2021 Benzinga

08:00AM EDT Vaccitech Announces Data Presentations at AASLDs GlobeNewswire Inc

Oct 13, 2021

08:00AM EDT Vaccitech to Present an Update on Its Chronic HBV Infection GlobeNewswire Inc

Oct 1, 2021

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 9, 2021

08:00AM EDT Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced that Bill Enright, Chief Executive Officer, will be presenting at the following investment conferences in September. GlobeNewswire Inc

Aug 12, 2021

08:25AM EDT Vaccitech Q2 EPS $(0.64) Down From $(0.45) YoY Benzinga

08:00AM EDT Vaccitech Reports Second Quarter 2021 Financial Results and Recent GlobeNewswire Inc

Jul 6, 2021

04:51PM EDT Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity Benzinga

10:19AM EDT Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B Benzinga

07:10AM EDT Arbutus Biopharma And Vaccitech Agree To Evaluate AB-729 In Combination With VTP-300 For Chronic HBV Infection RTTNews

07:03AM EDT Arbutus Biopharma And Vaccitech Announce Clinical Trial Collaboration Agreement To Evaluate RNAi Therapeutic, AB-729, In Combination With Immunotherapeutic, VTP-300, In Subjects With Chronic Hepatitis B Virus Infection Benzinga

07:00AM EDT Arbutus Biopharma and Vaccitech Announce Clinical Trial GlobeNewswire Inc

Jun 14, 2021

05:58PM EDT Vaccitech Q1 EPS $(1.90) Benzinga

05:49PM EDT Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced financial results for the quarter ended March 31, 2021, and provided an overview of the Companys recent corporate developments. GlobeNewswire Inc

Jun 1, 2021

08:00AM EDT Vaccitech to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire Inc

May 25, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021 Benzinga

07:21AM EDT William Blair Initiates Coverage On Vaccitech with Outperform Rating Benzinga

07:05AM EDT Jefferies Initiates Coverage On Vaccitech with Buy Rating, Announces Price Target of $28 Benzinga

07:02AM EDT Morgan Stanley Initiates Coverage On Vaccitech with Overweight Rating, Announces Price Target of $22 Benzinga

May 24, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2021 Benzinga

06:10AM EDT HC Wainwright & Co. Initiates Coverage On Vaccitech with Buy Rating, Announces Price Target of $25 Benzinga

May 23, 2021

10:06AM EDT The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation Benzinga

May 18, 2021

07:44AM EDT The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO Benzinga

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 13, 2021

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

May 8, 2021

12:10PM EDT The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

Apr 30, 2021

12:02PM EDT Vaccitech Opens For Trade At $13.62; IPO Priced At $17/ADS Benzinga

12:02PM EDT Opens For Trade At $13.62; IPO Priced At $17/ADS Benzinga

10:39AM EDT Vaccitech Shares Indicating $17 Benzinga

09:28AM EDT Vaccitech ADSs Will Open For Quote At 10:10 a.m. EST, Expected To Open For Trade After 10:20 a.m. EST; IPO Priced At $17/ADS Benzinga

Share